NCT04691661View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Parkinson Disease
Interventions
DRUG

Radotinib HCl 50 mg

Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.

DRUG

Placebo

Placebo

Trial Locations (7)

Unknown

NOT_YET_RECRUITING

CHRU de Lille - Hôpital Roger Salengro, Lille

RECRUITING

CHU Limoges, Limoges

RECRUITING

CHU de Lyon HCL, Lyon

RECRUITING

Hôpital Nantes-Hotel Dieu, Nantes

RECRUITING

Hôpital Pitié-Salpêtrière, Paris

RECRUITING

Chu La Miletrie, Poitiers

RECRUITING

CHU de Rouen, Rouen

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY